MedTrace Logo

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-03

No results posted yet for this study

Summary

Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.

Conditions

  • Recurrent Ovarian Cancer
  • Recurrent Epithelial Cancer of Ovary
  • Recurrent Epithelial Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Peritoneal Cancer
  • Recurrent Carcinoma of Ovary
  • Adenocarcinoma of Ovary

Interventions

BIOLOGICAL

Oregovomab

2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.

DRUG

Niraparib

300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.

Sponsors & Collaborators

  • Veristat, LLC

    collaborator UNKNOWN

  • Raptim Research

    collaborator OTHER

  • CanariaBio Inc.

    lead INDUSTRY

Principal Investigators

  • Sunil Gupta, MD, FRCPC · CanariaBio Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2026-12-30
Completion
2027-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335993 on ClinicalTrials.gov